Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources. | --- | --- | --- | --- | --- | --- ...

16 For example, a product candidate is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. Fast Track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical developmen ...

Codexis, Inc. (NASDAQ:CDXS) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Stephen Dilly - President, CEO & Director Kevin Norrett - COO Sriram Ryali - CFO Conference Call Participants Steven Mah - Cowen Company Brandon Couillard - Jefferies Matthew Hewitt - Craig-Hallum Operator Welcome to the Codexis Fourth Quarter and Full Year 2022 Earnings Conference Call. A question-and-answer session will follow the formal presentation. [Operator Instructions]. And now I'll turn th ...

Codexis, Inc. (NASDAQ:CDXS) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Brendan Strong - Argot Partners Dr. Stephen Dilly - President and Chief Executive Officer Kevin Norrett - Chief Operating Officer Ross Taylor - Chief Financial Officer Conference Call Participants Chad Wiatrowski - Cowen and Company Matthew Hewitt - Craig-Hallum Capital Group Operator Welcome to the Codexis Third Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-onl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) ____________________ ...

Codexis, Inc. (NASDAQ:CDXS) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Brendan Strong - Argot Partners John Nicols - President and Chief Executive Officer Ross Taylor - Chief Financial Officer Stephen Dilly - Board Member Conference Call Participants Steven Mah - Cowen and Company Matthew Hewitt - Craig-Hallum Ramakanth Swayampakula - H.C. Wainwright Operator Welcome to the Codexis Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a list ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Q2'2022 Results August 4, 2022 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to di ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) _________________________ ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Corporate Presentation May 2022 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to d ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Q1'2022 Results May 5, 2022 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to diffe ...